Latest Options News

Pacific Smiles Group has agreed to an unconditional $2.20 per share cash takeover offer from its majority shareholder Genesis Bidco, representing a 37.5% premium. The Independent Board Committee recommends shareholders accept the offer, pending no superior proposal and ongoing fairness confirmation.

Buru Energy has raised $2.35 million through a Share Purchase Plan and shortfall placement, bolstering funding for its Rafael Gas Project in Western Australia.

Aurumin Limited proposes a scheme of arrangement for acquisition by Brightstar Resources, with an independent expert confirming the deal is fair and reasonable. The transaction offers Aurumin shareholders exposure to a larger gold portfolio and enhanced market presence.

BHP Group Limited has updated its dividend announcement, revealing the dividend reinvestment plan price for the first half of fiscal 2025. The fully franked dividend of USD 0.60 per share will be paid on 25 September, with shareholders able to reinvest at a DRP price based on recent market transactions.

ABx Group’s subsidiary ABx3 has received a $2.7 million investment from Good Importing International, granting GII 70% ownership to develop the Sunrise Bauxite Project in Queensland. This funding kickstarts a 12–24 month program targeting regulatory approvals and mine planning, with further investment options on the horizon.

ARB Corporation Limited has updated its dividend announcement, confirming a fully franked ordinary dividend of AUD 0.35 per share and setting DRP and BSP prices at AUD 38.17 with a 2% discount.

Bindi Metals Limited has agreed to acquire up to an 80% interest in the Ravni gold project in Serbia’s prolific Raska mining district, accompanied by a $2.5 million capital raising to fund exploration activities.

Liontown Resources has secured a one-year deferral on debt repayments to Ford and halved its spodumene concentrate commitments, unlocking new sales opportunities amid evolving lithium markets.

PYC Therapeutics has reported positive safety outcomes from its Phase 1 trial of PYC-001 for Autosomal Dominant Optic Atrophy, paving the way for a global Phase 1/2 study later this year.

EVE Health Group has raised $1.1 million to accelerate the commercial rollout of its innovative pharmaceutical products Dyspro and Libbo, signaling strong investor confidence in its growth strategy.

Mammoth Minerals has intensified its exploration at the Excelsior Gold-Silver Project with a second drill rig, aiming to deliver its first resource estimate by Q4 2025. A comprehensive magnetics survey further sharpens targeting across multiple mineralised trends.

Austral Resources Australia Limited has extended the closing date for its $40 million placement offer to 20 October 2025, alongside an ASX suspension extension to 31 October to meet reinstatement conditions.